The partnership aims to deliver integrated digital pathology workflow solutions for mutual customers of both companies
Leica Biosystems has announced a partnership with Indica Labs to offer compatible digital pathology workflow solutions. (Credit: elvtimemaster from Pixabay)
Cancer diagnostics company Leica Biosystems has entered into a partnership with Indica Labs, a provider of computational pathology software and services, to offer compatible digital pathology workflow solutions.
The partnership is intended to deliver the integrated workflow solutions for mutual customers.
Indica Labs CEO Steven Hashagen said: “The Indica team is delighted to formalise our relationship with Leica Biosystems.
“The partnership solidifies our commitment to ensuring that Leica Biosystems state-of-the art slide scanners, reagents, and instrumentation can be coupled with our leading digital workflow and analytics software.
“Customers can rest assured that both companies are working proactively to meet the regulatory and technical integration needs of the industry.”
As per the agreement, both firms will maintain the ongoing file format compatibility between the Aperio GT 450 range of scanners of Leica Biosystems and Indica Labs Halo family of software solutions.
Also included in the Indica Labs Halo family of software solutions are image management workflow software and artificial intelligence (AI) enabled image analysis.
Leica Biosystems president Gustavo Perez said: “For customers using Leica Biosystems Aperio GT 450 family platforms who are seeking AI-enabled image analysis and image management applications, this new partnership can eliminate integration challenges and provides our customers with peace of mind when implementing a digital pathology workflow with Indica’s HALO product portfolio.”
In May this year, Indica Labs secured a CE-IVD mark for HALO Prostate AI, the company’s deep learning-based screening tool, which is designed to support pathologists in identifying as well as grading prostate cancer from core needle biopsy samples.